RLAY vs. CNTA, BLTE, OCUL, RXRX, TARS, AGIO, IRON, DNLI, HRMY, and IDYA
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), Ocular Therapeutix (OCUL), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.
Relay Therapeutics vs. Its Competitors
Centessa Pharmaceuticals (NASDAQ:CNTA) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Centessa Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
Centessa Pharmaceuticals currently has a consensus price target of $28.10, indicating a potential upside of 62.62%. Relay Therapeutics has a consensus price target of $17.25, indicating a potential upside of 407.35%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Centessa Pharmaceuticals.
82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Centessa Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Centessa Pharmaceuticals had 14 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Centessa Pharmaceuticals and 1 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.37 beat Centessa Pharmaceuticals' score of -0.29 indicating that Relay Therapeutics is being referred to more favorably in the news media.
Centessa Pharmaceuticals' return on equity of -40.39% beat Relay Therapeutics' return on equity.
Summary
Centessa Pharmaceuticals beats Relay Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RLAY) was last updated on 8/20/2025 by MarketBeat.com Staff
MarketBeat All Access